Literature DB >> 14577021

Cyclosporine absorption profiles in pediatric kidney and liver transplant patients.

J M Kovarik1, Peter F Hoyer, Robert Ettenger, Jeffrey Punch, Marianne Soergel.   

Abstract

Cyclosporine absorption profiling uses either the area under the concentration curve in the first 4 h post dose, AUC(0-4), or the concentration 2 h post dose (C2) to optimize immunosuppression in adult kidney and liver transplantation. We characterized C2 versus AUC(0-4) relationships over time after transplant and across transplant indications in 56 pediatric transplant patients. There were 36 kidney transplant patients aged 9.7+/-3.9 years. Nineteen of these patients were studied in the de novo period on day 7 post transplant and 17 in the maintenance phase more than 1 year post transplant. In addition, 20 liver transplant patients aged 8.9+/-4.2 years were studied in the maintenance phase. All patients had five blood samples collected over the 12-h dose interval that were analyzed by validated assay methods at a central laboratory. Pediatric C2 values were 1,463+/-658 ng/ml for de novo kidney, 954+/-322 ng/ml for maintenance kidney, and 619+/-339 ng/ml for maintenance liver transplant patients. C2 was a strong predictor of AUC(0-4) in all three pediatric groups, with coefficients of determination ( r(2)) ranging from 0.861 to 0.936. Although data were limited from the de novo period, the C2 versus AUC(0-4) regression was consistent over time after transplant and between transplant indications, with a regression slope of 2.50 in de novo kidney, 2.54 in maintenance kidney, and 2.76 in maintenance liver transplant recipients. These slopes were also comparable to that in adult maintenance kidney transplant patients (2.60). In conclusion, C2 versus AUC(0-4) relationships demonstrated consistency over time (de novo vs. maintenance phase), between transplant indications (kidney vs. liver), and across age groups (pediatric vs. adult patients). Average C2 values achieved with current pediatric cyclosporine dosing practices cluster around the target C2 ranges recommended for adults.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14577021     DOI: 10.1007/s00467-003-1260-8

Source DB:  PubMed          Journal:  Pediatr Nephrol        ISSN: 0931-041X            Impact factor:   3.714


  13 in total

1.  Refining immunosuppressive protocols in pediatric renal transplant recipients.

Authors:  P F Hoyer; U Vester
Journal:  Transplant Proc       Date:  2001 Nov-Dec       Impact factor: 1.066

Review 2.  Patient management by Neoral C(2) monitoring: an international consensus statement.

Authors:  Gary Levy; Eric Thervet; John Lake; Kazuharu Uchida
Journal:  Transplantation       Date:  2002-05-15       Impact factor: 4.939

3.  Recommendations for the implementation of Neoral C(2) monitoring in clinical practice.

Authors:  Edward Cole; Karsten Midtvedt; Atholl Johnston; James Pattison; Catherine O'Grady
Journal:  Transplantation       Date:  2002-05-15       Impact factor: 4.939

Review 4.  Cyclosporin pharmacokinetics in paediatric transplant recipients.

Authors:  G F Cooney; K Habucky; K Hoppu
Journal:  Clin Pharmacokinet       Date:  1997-06       Impact factor: 6.447

5.  Single-dose pharmacokinetics and tolerability of everolimus in stable pediatric renal transplant patients.

Authors:  R Van Damme-Lombaerts; N A Y Webb; P F Hoyer; J Mahan; J Lemire; R Ettenger; L McMahon; N Cambon; R Boger; J M Kovarik
Journal:  Pediatr Transplant       Date:  2002-04

Review 6.  Neoral use in the pediatric transplant recipient.

Authors:  S Dunn
Journal:  Transplant Proc       Date:  2000-05       Impact factor: 1.066

7.  Improved clinical outcomes for liver transplant recipients using cyclosporine monitoring based on 2-hr post-dose levels (C2).

Authors:  G Levy; P Burra; A Cavallari; C Duvoux; J Lake; A D Mayer; S Mies; S G Pollard; E Varo; F Villamil; A Johnston
Journal:  Transplantation       Date:  2002-03-27       Impact factor: 4.939

8.  High-throughput analysis of everolimus (RAD001) and cyclosporin A (CsA) in whole blood by liquid chromatography/mass spectrometry using a semi-automated 96-well solid-phase extraction system.

Authors:  L M McMahon; S Luo; M Hayes; F L Tse
Journal:  Rapid Commun Mass Spectrom       Date:  2000       Impact factor: 2.419

9.  Longitudinal evaluation of the pharmacokinetics of cyclosporin microemulsion (Neoral) in pediatric renal transplant recipients and assessment of C2 level as a marker for absorption.

Authors:  Richard Trompeter; Margaret Fitzpatrick; Carol Hutchinson; Atholl Johnston
Journal:  Pediatr Transplant       Date:  2003-08

10.  Everolimus in pediatric de nova renal transplant patients.

Authors:  Peter F Hoyer; Robert Ettenger; John M Kovarik; Nicholas J A Webb; Jacques Lemire; Mark Mentser; John Mahan; Chantal Loirat; Patrick Niaudet; R VanDamme-Lombaerts; Gisela Offner; Sabine Wehr; Virginia Moeller; Hartmut Mayer
Journal:  Transplantation       Date:  2003-06-27       Impact factor: 4.939

View more
  1 in total

Review 1.  To what extent does the understanding of pharmacokinetics of mycophenolate mofetil influence its prescription.

Authors:  Guido Filler; Nathalie Lepage
Journal:  Pediatr Nephrol       Date:  2004-07-15       Impact factor: 3.714

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.